In addition, CDR1as, in contrast to its role in BC and lung adenocarcinoma, is downregulated in cisplatin-resistant ovarian cancer tissues, and it decreases the resistance of cells to cisplatin via the miR-1270/SCAI axis78. Here, LINC00632 is linked to ovarian cancer.